AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27932196 — intervention group
Group type: EXPERIMENTAL
Intervention: mVLT using 2.5-mLkg-1 boluses of Ringer's acetate
Number of subjects: 0
Study 24907853 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial skin sealant
Number of subjects: 140
Study 24907853 — intervention group
Group type: COMPARATOR
Intervention: Bare skin
Number of subjects: 140
Study 22682671 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus exercise intervention delivered over 6 months
Number of subjects: 208
Study 22682671 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 208
Study 19579605 — intervention group
Group type: COMPARATOR
Intervention: 5-day terlipressin treatment (Group A)
Number of subjects: 25
Study 19579605 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day terlipressin treatment (Group B)
Number of subjects: 25
Study 17805339 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO), administered for > or = 24 days
Number of subjects: 71
Study 17805339 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered for > or = 24 days
Number of subjects: 71
Study 14985664 — intervention group
Group type: COMPARATOR
Intervention: Sterile gloves
Number of subjects: 816
Study 14985664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean nonsterile gloves
Number of subjects: 816
Study 11890385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized, 30‐minute Reiki session
Number of subjects: 23
Study 9445498 — intervention group
Group type: COMPARATOR
Intervention: Nucleotide formula
Number of subjects: 311
Study 9445498 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 311
Study 9445498 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 311
Study 8522777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 150
Study 8522777 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin
Number of subjects: 150
Study 8522777 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefuroxime
Number of subjects: 150
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 2 ml (0.75%)
Number of subjects: 120
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 3 ml (0.5%)
Number of subjects: 120
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 6 ml (0.25%)
Number of subjects: 120
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg with epinephrine 1:200,000 in 9 ml (0.166%)
Number of subjects: 120
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 7.5 mg in 3 ml (0.25%)
Number of subjects: 120
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 15 mg in 3 ml (0.5%)
Number of subjects: 120
Study 2236712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 22.5 mg in 3 ml (0.75%)
Number of subjects: 120
Study 282482 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion hydrochloride (Tenuate Dospan)
Number of subjects: 0
Study 282482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31132978 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg melatonin plus regular treatments
Number of subjects: 41
Study 31132978 — intervention group
Group type: COMPARATOR
Intervention: Regular treatments only
Number of subjects: 41
Study 28806487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ma-Pi 2 diet
Number of subjects: 12
Study 28806487 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 12
Study 25547503 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus erlotinib
Number of subjects: 720
Study 25547503 — intervention group
Group type: COMPARATOR
Intervention: sorafenib plus placebo
Number of subjects: 720
Study 24132249 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 142
Study 24132249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 21341394 — intervention group
Group type: COMPARATOR
Intervention: PSI = 5
Number of subjects: 278
Study 21341394 — intervention group
Group type: COMPARATOR
Intervention: CURB-65 ≥ 3
Number of subjects: 278
Study 21341394 — intervention group
Group type: COMPARATOR
Intervention: APACHE II ≥ 25
Number of subjects: 278
Study 19057451 — intervention group
Group type: EXPERIMENTAL
Intervention: US guidance
Number of subjects: 152
Study 19057451 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 152
Study 17873254 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid-supported patient choice
Number of subjects: 0
Study 17873254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-supported choice of either intervention
Number of subjects: 0
Study 17873254 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid-supported choice of either intervention
Number of subjects: 0
Study 17873254 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (control)
Number of subjects: 0
Study 15312228 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (initial rate 9 microg kg(‐1) h(‐1), titrated before adding propofol [0.5 mg kg(‐1) h(‐1)] during days 1-3, midazolam [0.03 mg kg(‐1) h(‐1)] during days 4 and 5)
Number of subjects: 121
Study 15312228 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 121
Study 15312228 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic-based regimen (fentanyl or morphine with propofol and midazolam)
Number of subjects: 121
Study 11597377 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 35
Study 11597377 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouthwash
Number of subjects: 35
Study 9816659 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with PDS II-cord augmentation (G1)
Number of subjects: 200
Study 9816659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute BTB ligament replacement (G2)
Number of subjects: 200
Study 9816659 — intervention group
Group type: COMPARATOR
Intervention: Late BTB ligament replacement (G3)
Number of subjects: 200
Study 9816659 — intervention group
Group type: COMPARATOR
Intervention: Late BTB ligament replacement with PDS II-cord augmentation (G4)
Number of subjects: 200
Study 7912875 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperon (15-30 mg)
Number of subjects: 100
Study 7912875 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (4-10 mg)
Number of subjects: 100
Study 2731086 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (15 mg daily)
Number of subjects: 25
Study 1140623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metiamide
Number of subjects: 8
Study 1140623 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study 30461621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy by low-temperature plasma
Number of subjects: 72
Study 30461621 — intervention group
Group type: COMPARATOR
Intervention: Tonsil-pecking (Control)
Number of subjects: 72
Study 28404647 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA)
Number of subjects: 127
Study 28404647 — intervention group
Group type: COMPARATOR
Intervention: Chest Tube Drainage (CTD)
Number of subjects: 127
Study 28404647 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA) in SSP subgroup
Number of subjects: 127
Study 28404647 — intervention group
Group type: COMPARATOR
Intervention: Chest Tube Drainage (CTD) in SSP subgroup
Number of subjects: 127
Study 26080850 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (20 g/d), EPA (3.3 g/d), branched-chain amino acids (8 g/d)
Number of subjects: 104
Study 26080850 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary counseling and routine nutritional supports only)
Number of subjects: 104
Study 23010883 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 36 months
Number of subjects: 7808
Study 23010883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 23010883 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 7808
Study 20583512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii with Marble Mania (experimental group)
Number of subjects: 21
Study 20583512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no game play)
Number of subjects: 21
Study 21158148 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO pretreatment twice (Group A)
Number of subjects: 20
Study 21158148 — intervention group
Group type: COMPARATOR
Intervention: HBO pretreatment 5 times (Group B)
Number of subjects: 20
Study 21158148 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO pretreatment once per day for 2 days (HBO group)
Number of subjects: 20
Study 21158148 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n=10)
Number of subjects: 20
Study 21158148 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO pretreatment once per day for 3 days (HBO group)
Number of subjects: 20
Study 15858959 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii (250 mg daily for 5 days)
Number of subjects: 200
Study 15858959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12529661 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF mobilization
Number of subjects: 342
Study 10476018 — intervention group
Group type: EXPERIMENTAL
Intervention: Students taught by Patient Partners
Number of subjects: 0
Study 10476018 — intervention group
Group type: COMPARATOR
Intervention: Students taught by Consultants
Number of subjects: 0
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive surgery (surgery alone)
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 244
Study 8756387 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone (control group)
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection (radical or wide margin)
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete resection (marginal or intralesional margin)
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after incomplete surgery
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic response (good)
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic response (poor)
Number of subjects: 244
Study 8756387 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical margins (radical, wide, marginal, intralesional)
Number of subjects: 244
Study 1879246 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (SF‐RI 1)
Number of subjects: 69
Study 1879246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 7038925 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole standard dose
Number of subjects: 0
Study 7038925 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole high-dose schedule
Number of subjects: 0
Study 7038925 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine standard course
Number of subjects: 0
Study 30585388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 984
Study 30585388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 29498155 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven intervention asking providers to self-identify opioid prescribing practices and providing actual prescribing data
Number of subjects: 109
Study 29498155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study 28846646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 113
Study 28846646 — intervention group
Group type: COMPARATOR
Intervention: Health-education (HE)
Number of subjects: 113
Study 24812024 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25, 50, or 100mg) or placebo with smoking cessation counseling and 21 mg nicotine patch daily
Number of subjects: 348
Study 24431257 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT)
Number of subjects: 26
Study 24431257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Kinesiology Taping)
Number of subjects: 26
Study 20643882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Number of subjects: 10
Study 20643882 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 10
Study 18390968 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6244 (50% MTD, 100 mg bid)
Number of subjects: 57
Study 18390968 — intervention group
Group type: COMPARATOR
Intervention: AZD6244 (MTD, 200 mg bid)
Number of subjects: 57
Study 16624830 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich diet (cruciferous vegetables, no supplementation)
Number of subjects: 90
Study 16624830 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal isocaloric diet (adequate fruits and vegetables)
Number of subjects: 90
Study 16624830 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of flavonoids (green tea and soy products)
Number of subjects: 90
Study 16624830 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal isocaloric diet)
Number of subjects: 90
Study 12682771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) exercises
Number of subjects: 28
Study 11714001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HF)
Number of subjects: 480
Study 11714001 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFR)
Number of subjects: 480
Study 8974898 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 D-video system
Number of subjects: 76
Study 8974898 — intervention group
Group type: COMPARATOR
Intervention: 2 D-video system
Number of subjects: 76
Study 8272201 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered as subcutaneous injection of 3 million units 5 times a week for 8 weeks
Number of subjects: 9
Study 8272201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3826277 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.5%)
Number of subjects: 20
Study 3826277 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive demand
Number of subjects: 20
Study 3826277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cognitive demand
Number of subjects: 20
Study 3826277 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-antagonism
Number of subjects: 20
Study 29713151 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment educational intervention
Number of subjects: 464
Study 29713151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 464
Study 27756441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream-type adhesive
Number of subjects: 300
Study 27756441 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-type adhesive
Number of subjects: 300
Study 27756441 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic sodium chloride solution)
Number of subjects: 300
Study 24996807 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed malaria-related fever
Number of subjects: 432
Study 24996807 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 lymphocytes
Number of subjects: 432
Study 24996807 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment started before inclusion
Number of subjects: 432
Study 24996807 — intervention group
Group type: EXPERIMENTAL
Intervention: History of symptomatic malaria in early pregnancy
Number of subjects: 432
Study 24996807 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile episodes attributable to malaria
Number of subjects: 432
Study 24942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend support for healthy eating
Number of subjects: 633
Study 24942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Coworker support for healthy eating
Number of subjects: 633
Study 24942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support for physical activity
Number of subjects: 633
Study 24942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Family social undermining for healthy eating
Number of subjects: 633
Study 23018299 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 30
Study 23018299 — intervention group
Group type: COMPARATOR
Intervention: Normal ventilation
Number of subjects: 30
Study 23018299 — intervention group
Group type: COMPARATOR
Intervention: Hypoventilation
Number of subjects: 30
Study 21046483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate supplementation (67.5 mmol/day of potassium bicarbonate or sodium bicarbonate)
Number of subjects: 153
Study 21046483 — intervention group
Group type: COMPARATOR
Intervention: No-bicarbonate groups (67.5 mmol/day of placebo or potassium chloride)
Number of subjects: 153
Study 17692153 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily for 6 weeks, increased to 20 mg after 6 weeks, then to 40 mg after 12 weeks
Number of subjects: 68
Study 17692153 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg daily for 6 weeks, increased to 40 mg after 6 weeks, then to 80 mg after 12 weeks
Number of subjects: 68
Study 17692153 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin and atorvastatin (both groups)
Number of subjects: 68
Study 16254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonistein 30 mg once daily for 14 days
Number of subjects: 30
Study 16254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonistein 60 mg once daily for 14 days
Number of subjects: 30
Study 16254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonistein 120 mg once daily for 14 days
Number of subjects: 30
Study 16254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonistein (all doses)
Number of subjects: 30
Study 12121609 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgery with two-piece implants (group A)
Number of subjects: 82
Study 12121609 — intervention group
Group type: COMPARATOR
Intervention: Two-stage surgery with two-piece implants (group B, control)
Number of subjects: 82
Study 12121609 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgery with one-piece implants (group C)
Number of subjects: 82
Study 12121609 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 82
Study 10468965 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy (0.25 IU/Kg/week, 0.125 IU/kg/week for the first four weeks)
Number of subjects: 35
Study 10468965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10468965 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy
Number of subjects: 35
Study 10468965 — intervention group
Group type: EXPERIMENTAL
Intervention: Open GH treatment after placebo
Number of subjects: 35
Study 8862492 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day clomiphene citrate for 3 days
Number of subjects: 28
Study 8862492 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/day clomiphene citrate for 5 days
Number of subjects: 28
Study 1363657 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 781
Study 1363657 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10-20 mg
Number of subjects: 781
Study 1363657 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg (in elderly)
Number of subjects: 781
Study 1363657 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 781
Study 6092317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 52
Study 6092317 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin
Number of subjects: 52
Study 29562794 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdates induction (≥41 weeks)
Number of subjects: 854
Study 29562794 — intervention group
Group type: COMPARATOR
Intervention: Term induction (37–40w6d)
Number of subjects: 854
Study 30499380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (digital stethoscope and HHE)
Number of subjects: 8
Study 30499380 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard stethoscope only)
Number of subjects: 8
Study 30499380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 8
Study 30499380 — intervention group
Group type: COMPARATOR
Intervention: Difference between control and intervention groups
Number of subjects: 8
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/significant-CVD group
Number of subjects: 240
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum-SAA and HDL3-SAA
Number of subjects: 240
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HDL3-SAA and HDL3-LCAT activity
Number of subjects: 240
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CVD-burden and serum-SAA
Number of subjects: 240
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CVD-burden and HDL3-SAA
Number of subjects: 240
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CVD-burden and HDL3-LCAT activity
Number of subjects: 240
Study 26647373 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL3-SAA
Number of subjects: 240
Study 24961493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine in patients with SBP <115 mmHg
Number of subjects: 2110
Study 24961493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine in patients with 115≤ SBP <130 mmHg
Number of subjects: 2110
Study 24961493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine in patients with SBP ≥130 mmHg
Number of subjects: 2110